Neopharmed Gentili

Trials

2 participants · First posted Oct 31, 2014

Recruiting

NCT06826794

VentilO Prospective Study

76 participants · First posted Feb 14, 2025

Completed

NCT03779971

Energy Value of Lentils and Chickpeas

18 participants · First posted Dec 19, 2018

Drugs

View all 6 →

Biotech

Approved

Lentil

NP-003 (NeoPharm)

Small Molecule

Approved

Gentian Violet

Manufacturer: Savage laboratories inc div altana inc, Key pharmaceuticals inc sub schering plough corp

Conditions: Bacterial Infection of the umbilical cord area, Fungal Infection of the umbilical cord area +2 more

C₂₅H₃₀N₃

Organizations

View all 11 →

ISTITUTO GENTILI S.R.L.

Norway

Deborah Gentile

Germany

NEOPHARM LIMITED

Hong Kong, China

News

last year

BioCryst Pharmaceuticals Divests European ORLADEYO Rights for $264 Million to Achieve Debt-Free Status

last year

uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy

last year

Trials

Single Arm Post-marketing Study of SC20 Colonoscope

VentilO Prospective Study

Energy Value of Lentils and Chickpeas

Drugs

Lentil

NP-003 (NeoPharm)

Gentian Violet

Organizations

ISTITUTO GENTILI S.R.L.

Deborah Gentile

NEOPHARM LIMITED

News

BioCryst Pharmaceuticals Divests European ORLADEYO Rights for $264 Million to Achieve Debt-Free Status

uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy

uniQure Doses First Patient in Phase I/IIa Trial of AMT-260 for Refractory Mesial Temporal Lobe Epilepsy